182 related articles for article (PubMed ID: 27443511)
41. Acute Erythroleukemias, Acute Megakaryoblastic Leukemias, and Reactive Mimics: A Guide to a Number of Perplexing Entities.
Wang SA; Hasserjian RP
Am J Clin Pathol; 2015 Jul; 144(1):44-60. PubMed ID: 26071461
[TBL] [Abstract][Full Text] [Related]
42. The prognostic significance of proerythroblasts in acute erythroleukemia.
Kowal-Vern A; Cotelingam J; Schumacher HR
Am J Clin Pathol; 1992 Jul; 98(1):34-40. PubMed ID: 1615923
[TBL] [Abstract][Full Text] [Related]
43. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
[TBL] [Abstract][Full Text] [Related]
44. Clinicopathological evolution and multilineage involvement in erythroleukemia: report of a case.
Cuneo A; Gretel Carli M; Piva N; Fagioli F; Vandenberghe E; Dal Cin P; Castoldi G; Van Den Berghe H
Haematologica; 1991; 76(3):235-7. PubMed ID: 1743594
[TBL] [Abstract][Full Text] [Related]
45. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count.
Chan GC; Wang WC; Raimondi SC; Behm FG; Krance RA; Chen G; Freiberg A; Ingram L; Butler D; Head DR
Leukemia; 1997 Feb; 11(2):206-11. PubMed ID: 9009082
[TBL] [Abstract][Full Text] [Related]
46. The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS.
Alkharabsheh O; Al-Kali A; Saadeh S; He R; Viswanatha D; Greipp P; Reichard K; Shah M; Gangat N; Patnaik M; Hogan W; Litzow M; Alkhateeb H; Nguyen PL
Am J Hematol; 2018 Nov; 93(11):E355-E357. PubMed ID: 30074268
[No Abstract] [Full Text] [Related]
47. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.
Nagai K; Kohno T; Chen YX; Tsushima H; Mori H; Nakamura H; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M; Bennett JM
Leuk Res; 1996 Jul; 20(7):563-74. PubMed ID: 8795690
[TBL] [Abstract][Full Text] [Related]
48. Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia.
Courville EL; Wu Y; Kourda J; Roth CG; Brockmann J; Muzikansky A; Fathi AT; de Leval L; Orazi A; Hasserjian RP
Mod Pathol; 2013 Jun; 26(6):751-61. PubMed ID: 23307061
[TBL] [Abstract][Full Text] [Related]
49. Changes in the Updated 2016: WHO Classification of the Myelodysplastic Syndromes and Related Myeloid Neoplasms.
Bennett JM
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):607-609. PubMed ID: 27693133
[TBL] [Abstract][Full Text] [Related]
50. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study.
Bernstein SH; Brunetto VL; Davey FR; Wurster-Hill D; Mayer RJ; Stone RM; Schiffer CA; Bloomfield CD
J Clin Oncol; 1996 Sep; 14(9):2486-94. PubMed ID: 8823327
[TBL] [Abstract][Full Text] [Related]
51. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy.
Estey E; Thall P; Beran M; Kantarjian H; Pierce S; Keating M
Blood; 1997 Oct; 90(8):2969-77. PubMed ID: 9376577
[TBL] [Abstract][Full Text] [Related]
52. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
[TBL] [Abstract][Full Text] [Related]
53. Essential thrombocythemia terminating in pure erythroleukemia.
Kreft A; Burg J; Fischer T; Kirkpatrick CJ
Am J Hematol; 2004 Oct; 77(2):140-3. PubMed ID: 15389906
[TBL] [Abstract][Full Text] [Related]
54. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
[TBL] [Abstract][Full Text] [Related]
55. A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria.
Margolskee E; Mikita G; Rea B; Bagg A; Zuo Z; Sun Y; Goswami M; Wang SA; Oak J; Arber DA; Allen MB; George TI; Rogers HJ; Hsi E; Hasserjian RP; Orazi A
Mod Pathol; 2018 Jun; 31(6):873-880. PubMed ID: 29403082
[TBL] [Abstract][Full Text] [Related]
56. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
Wimazal F; Krauth MT; Vales A; Böhm A; Agis H; Sonneck K; Aichberger KJ; Mayerhofer M; Simonitsch-Klupp I; Müllauer L; Sperr WR; Valent P
Leuk Lymphoma; 2006 Mar; 47(3):451-60. PubMed ID: 16396768
[TBL] [Abstract][Full Text] [Related]
57. Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome.
Suciu S; Kuse R; Weh HJ; Hossfeld DK
Cancer Genet Cytogenet; 1990 Jan; 44(1):15-26. PubMed ID: 2293879
[TBL] [Abstract][Full Text] [Related]
58. Blast counts are lower in the aspirate as compared to trephine biopsy in acute myeloid leukemia and myelodysplastic syndrome expressing CD56.
Drexler B; Tzankov A; Martinez M; Baerlocher S; Passweg JR; Dirnhofer S; Tsakiris DA; Dirks J
Int J Lab Hematol; 2021 Oct; 43(5):1078-1084. PubMed ID: 33709561
[TBL] [Abstract][Full Text] [Related]
59. Myeloid disorders with deletion of 5q as the sole karyotypic abnormality: the clinical and pathologic spectrum.
Washington LT; Doherty D; Glassman A; Martins J; Ibrahim S; Lai R
Leuk Lymphoma; 2002 Apr; 43(4):761-5. PubMed ID: 12153162
[TBL] [Abstract][Full Text] [Related]
60. Transcription patterning of uncoupled proliferation and differentiation in myelodysplastic bone marrow with erythroid-focused arrays.
Lee YT; Miller LD; Gubin AN; Makhlouf F; Wojda U; Barrett AJ; Liu ET; Miller JL
Blood; 2001 Sep; 98(6):1914-21. PubMed ID: 11535529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
